Clinical Trials Browser

Lung Neoplasms, Small Cell Lung Carcinoma

Diabetes Mellitus, Insulin-Dependent, 12, Biliary Tract Neoplasms, Carcinoma

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms

Cholangiocarcinoma

Head and Neck Neoplasms

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular, Liver Neoplasms

Uterine Cervical Neoplasms, Ovarian Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms

Carcinoma, Hepatocellular

Colorectal Neoplasms

Carcinoma, Non-Small-Cell Lung

Colorectal Neoplasms

Carcinoma, Renal Cell, Kidney Neoplasms

Uterine Cervical Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms

Small Cell Lung Carcinoma

Carcinoma, Non-Small-Cell Lung

Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms

Diabetes Mellitus, Insulin-Dependent, 12, Multiple Myeloma

Thyroid Carcinoma, Anaplastic

Squamous Cell Carcinoma of Head and Neck

Urinary Bladder Neoplasms

Colorectal Neoplasms

Prostatic Neoplasms

Urinary Bladder Neoplasms

Pancreatic Neoplasms

Small Cell Lung Carcinoma

Carcinoma, Non-Small-Cell Lung

Clinical Trials

Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer

Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)

Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers

Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma

Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients

Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer

SIRT With Tremelimumab and Durvalumab for Resectable HCC

Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer

Cryoablation and Arterial Infusion of SD-101 in Combination with Durvalumab and Tremelimumab

Immunotherapy Combined With Y-90 and SBRT for Colorectal Liver Metastases

Induction

Tremelimumab and Durvalumab in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery

Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma

Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers

A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC

Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition

A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab

Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant

Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer

Durvalumab With or Without Tremelimumab in Treating Participants With Stage II-IVA Oropharyngeal Squamous Cell Cancer

TRIO Bladder

Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma

Intradermal Injection of Anti-CTLA-4 in Patients With Stage I/II Melanoma

Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver

CP-675,206 in Combination With Short Term Androgen Deprivation in Patients With Stage D0 Prostate Cancer

Study of CP-675,206 in Bacillus Calmette-Guerin (BCG)-Resistant Bladder Cancer

Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer

SGI-110 Plus Durvalumab/Tremelimumab in SCLC

GEFTREM